Scarica l'app Stockscreener
40.41
0.05%
0.02
Dopo l'orario di chiusura:
40.41
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché APLS Giù?
Forum
Previsione
Apellis Pharmaceuticals Inc Borsa (APLS) Ultime notizie
Biogen’s Apellis Deal Reshapes Growth Outlook And Valuation Story - Yahoo Finance
APLS PE Ratio & Valuation, Is APLS Overvalued - Intellectia AI
Biogen Bets Big on Kidney Drugs with USD 5.6 Billion Apellis Pharmaceuticals Deal - medicaldialogues.in
Apellis Pharmaceuticals (APLS) hits 2-year high on 140% upside from Biogen merger - MSN
Biogen (NASDAQ: BIIB) plans tender offer to acquire Apellis (APLS); materials pending - Stock Titan
Deal Dispatch: McCormick, Unilever Merge, Sysco Acquires Jetro Restaurant Depot For $29 Billion, QVC Considers Bankruptcy - Benzinga
Biogen to acquire Apellis in $5.6 billion deal - Ophthalmology Times
Apellis Pharmaceuticals (NASDAQ:APLS) Downgraded by Roth Mkm to "Hold" - MarketBeat
Comparing Apellis Pharmaceuticals With Industry Competitors In Biotechnology Industry - Sahm
Apellis surges on $5.6B buyout deal with Biogen - MSN
APLS Stock Soars 140% Today – Here’s Everything To Know About Apellis' Massive $5.6B Deal With Biogen - Stocktwits
Biogen’s $5.6 Billion Apellis Buy Drives Top Trading Volume Amid Share Price Slide - Bitget
Why Biogen Is Paying $5.6B to Buy Apellis Pharma - MedCity News
Apellis Pharmaceuticals (APLS): Mizuho Raises Price Target Amids - GuruFocus
Mizuho Increases Apellis Pharmaceuticals (NASDAQ:APLS) Price Target to $41.00 - MarketBeat
Apellis Pharmaceuticals (NASDAQ:APLS) Downgraded to "Hold" Rating by Jefferies Financial Group - MarketBeat
Apellis Pharmaceuticals (NASDAQ:APLS) Downgraded to "Hold" Rating by William Blair - MarketBeat
Apellis Pharmaceuticals (NASDAQ:APLS) Lowered to Hold Rating by Citigroup - MarketBeat
H.C. Wainwright raises Biogen stock price target on Apellis deal - Investing.com
Apellis Pharmaceuticals (NASDAQ:APLS) Emerges as a Prime Affordable Growth (GARP) Candidate - ChartMill
Biogen to Acquire Apellis Pharmaceuticals in $5.6 Billion Deal - eHealth Magazine
Roth/MKM downgrades Apellis stock rating on Biogen acquisition - Investing.com
SHAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Apellis Pharmaceuticals, Inc. (NASDAQ: APLS) - Sahm
Apellis Pharmaceuticals (APLS) Moves 135.4% Higher: Will This Strength Last? - qz.com
Biogen Acquires Apellis for $5.6B, Shares Dip | Strategic Immunology MoveNews and Statistics - IndexBox
APLS: Barclays Raises Price Target for Apellis Pharmaceuticals | - GuruFocus
APLS: JP Morgan Downgrades Apellis Pharmaceuticals, Raises Price Target | APLS Stock News - GuruFocus
Biogen, on the heels of a $5.6B buyout, turns its sights to early-stage assets - BioPharma Dive
How The Apellis Pharmaceuticals (APLS) Investment Story Is Shifting With New Deals And Analyst Revisions - finance.yahoo.com
Apellis Pharmaceuticals, Inc. (APLS) Stock Forecasts - finance.yahoo.com
JPMorgan Chase & Co. Reaffirms Neutral Rating for Apellis Pharmaceuticals (NASDAQ:APLS) - MarketBeat
Watch Biogen Buys Apellis for $5.6B to Expand Kidney Drugs - Bloomberg.com
American Biogen bought assets of Apellis Pharmaceuticals for $5.6 billion - AKM.RU
Apellis Pharmaceuticals (NASDAQ:APLS) Stock Price Expected to Rise, Barclays Analyst Says - MarketBeat
Biogen to acquire Apellis Pharmaceuticals for $5.6 billion By Investing.com - Investing.com Canada
Biogen’s $5.6bn Apellis Deal Delivers Windfall for Worldwide Healthcare Trust - TipRanks
Apellis Pharmaceuticals (NASDAQ:APLS) Sees Large Volume IncreaseWhat's Next? - MarketBeat
APLS Downgraded by Raymond James to Market Perform | APLS Stock News - GuruFocus
A Look At Apellis Pharmaceuticals (APLS) Valuation After Its Sharp Recent Share Price Surge - simplywall.st
Worldwide Healthcare Trust PLCBiogen, Inc. to acquire WWH portfolio company, Apellis Pharmaceuticals, Inc. - bolsamania.com
Apellis Pharmaceuticals (NASDAQ:APLS) Receives "Market Perform" Rating from Raymond James Financial - MarketBeat
Mizuho raises Apellis stock price target to $41 on Biogen deal - investing.com
Biogen Enters $5.6 Billion Agreement to Acquire Apellis Pharmaceuticals - Pharmaceutical Executive
APLS Downgraded by Citigroup: Target Price Lowered to $41.00 | A - GuruFocus
This PPG Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Wednesday - Benzinga
Biogen to Acquire Apellis for $5.6B to Strengthen Immunology Portfolio - finance.yahoo.com
Apellis Pharmaceuticals (NASDAQ:APLS) Given Neutral Rating at Citigroup - MarketBeat
Apellis Pharmaceuticals Stock Nears Biogen’s $5.6 Billion Bid for Syfovre and Empaveli - TechStock²
Apellis Pharmaceuticals (APLS) Surges 135.4%: Can This Momentum Be Sustained? - Bitget
Apellis Pharmaceuticals (NASDAQ:APLS) Given "Neutral" Rating at HC Wainwright - MarketBeat
Biogen stock price target raised to $245 by Canaccord on Apellis deal - Investing.com
APLS Downgraded by HC Wainwright & Co. with Price Target Lowered - GuruFocus
JPMorgan Downgrades Apellis Pharmaceuticals to Neutral From Overweight, Adjusts Price Target to $41 From $37 - MarketScreener
Biogen uplifts rare disease pipeline with $5.6bn Apellis buyout - finance.yahoo.com
Apellis Pharmaceuticals to be Acquired by Biogen in Merger - TipRanks
Biogen bolsters immunology offerings with $5.6bn Apellis buy - bioxconomy.com
Biogen bets on $5.6 billion buyout of Apellis in rare disease push - WTAQ
Raymond James downgrades Apellis stock rating on Biogen acquisition - Investing.com
Cantor Fitzgerald cuts Apellis stock rating on Biogen acquisition - Investing.com
0.49%
1.47%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):